精神病高危个体多巴胺与谷氨酸的活体成像荟萃分析
结果显示仅遗传高危个体丘脑Glx浓度升高,其余神经化学指标无显著差异,且遗传高危个体纹状体D2/D3受体可用性变异性降低。
要点
- 遗传高危个体丘脑谷氨酸+谷氨酰胺浓度升高(Hedges' g=0.36)。
- 高危个体与对照在纹状体多巴胺功能、D2/D3受体、前额叶及海马谷氨酸无显著差异。
- 临床高危个体突触前多巴胺功能差异随时间减小,提示研究异质性。
核心结论
- 除丘脑谷氨酸浓度升高外,精神病高危个体与对照在多数多巴胺和谷氨酸指标上无显著差异。
- 未发现高危个体多巴胺或谷氨酸指标变异性增加,但研究间异质性大,不能排除临床意义差异。
研究设计与样本
- 系统综述与荟萃分析,检索EMBASE、PsycINFO和Medline(1960年1月1日至2020年11月26日)。
- 计算标准化均数差,并分析指标变异性差异。
主要发现
- 遗传高危个体丘脑谷氨酸+谷氨酰胺浓度升高(Hedges' g=0.36,95% CI:0.12-0.61,p=0.003)。
- 高危个体与对照在纹状体突触前多巴胺功能、纹状体D2/D3受体可用性、前额叶皮质谷氨酸或Glx、海马谷氨酸或Glx、基底节Glx均无显著差异。
- 遗传高危个体纹状体D2/D3受体可用性变异性降低(log CVR=-0.24,95% CI:-0.46至-0.02,p=0.03)。
- 临床高危个体突触前多巴胺功能与对照的差异随时间减小(估计值=-0.06,95% CI:-0.11至-0.007,p=0.025)。
关键数值与推荐
- 纳入标准为纹状体突触前多巴胺功能、纹状体多巴胺受体可用性或谷氨酸功能的分子影像测量。
临床怎么用
- 丘脑谷氨酸浓度可能作为遗传高危个体的潜在生物标志物,但其他指标尚不支持常规临床使用。
- 临床高危个体的多巴胺功能差异可能受研究年份影响,解读结果需考虑异质性。
局限性
- 研究间存在显著异质性,不能排除临床意义差异的存在。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dopaminergic and glutamatergic dysfunction is believed to play a central role in the pathophysiology of schizophrenia. However, it is unclear if abnormalities predate the onset of schizophrenia in individuals at high clinical or genetic risk for the disorder. We systematically reviewed and meta-analyzed studies that have used neuroimaging to investigate dopamine and glutamate function in individuals at increased clinical or genetic risk for psychosis. EMBASE, PsycINFO and Medline were searched form January 1, 1960 to November 26, 2020. Inclusion criteria were molecular imaging measures of striatal presynaptic dopaminergic function, striatal dopamine receptor availability, or glutamate function. Separate meta-analyses were conducted for genetic high-risk and clinical high-risk individuals. We calculated standardized mean differences between high-risk individuals and controls, and investigated whether the variability of these measures differed between the two groups. Forty-eight eligible studies were identified, including 1,288 high-risk individuals and 1,187 controls. Genetic high-risk individuals showed evidence of increased thalamic glutamate + glutamine (Glx) concentrations (Hedges' g=0.36, 95% CI: 0.12-0.61, p=0.003). There were no significant differences between high-risk individuals and controls in striatal presynaptic dopaminergic function, striatal D2/D3 receptor availability, prefrontal cortex glutamate or Glx, hippocampal glutamate or Glx, or basal ganglia Glx. In the meta-analysis of variability, genetic high-risk individuals showed reduced variability of striatal D2/D3 receptor availability compared to controls (log coefficient of variation ratio, CVR=-0.24, 95% CI: -0.46 to -0.02, p=0.03). Meta-regressions of publication year against effect size demonstrated that the magnitude of differences between clinical high-risk individuals and controls in presynaptic dopaminergic function has decreased over time (estimate=-0.06, 95% CI: -0.11 to -0.007, p=0.025). Thus, other than thalamic glutamate concentrations, no neurochemical measures were significantly different between individuals at risk for psychosis and controls. There was also no evidence of increased variability of dopamine or glutamate measures in high-risk individuals compared to controls. Significant heterogeneity, however, exists between studies, which does not allow to rule out the existence of clinically meaningful differences.
引用
- McCutcheon RA, Merritt K, Howes OD, et al. Dopamine and glutamate in individuals at high risk for psychosis: a meta-analysis of in vivo imaging findings and their variability compared to controls. World Psychiatry. 2021. PMID: 34505389. doi:10.1002/wps.20893
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。